Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2025 : Emerging Opportunities, Disruptive Innovations, and Growth Roadmap by 2031

Los Angeles, United States - QY Research has unveiled its latest study titled "Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031." This newly released report delivers a comprehensive overview of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, analyzing the forces shaping its growth trajectory and providing valuable insights for stakeholders, investors, and industry professionals.

The global market for Duchenne Muscular Dystrophy (DMD) Therapeutics was estimated to be worth US$ 2170 million in 2024 and is forecast to a readjusted size of US$ 4776 million by 2031 with a CAGR of 13.1% during the forecast period 2025-2031.

Download Free Sample PDF Report (with full TOC, tables, and charts) To Explore Detailed Insights and Forecasts @ https://qyresearch.in/request-sample/medical-care-global-duchenne-muscular-dystrophy-dmd-therapeutics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne-a mutation in the DMD gene-happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Competitive Landscape: -

Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals

The competitive landscape is a must-have information for the market players to withstand the competition present in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. This further helps the market participants to develop effective strategies to optimize their market positions. Moreover, the competitive analysis helps them to determine potential advantages as well as barriers within the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. This way, they can monitor how their competitors are implementing various strategies including pricing, marketing, and distribution.

The Duchenne muscular dystrophy (DMD) treatment market is primarily driven by the following factors:

I. Disease Burden and Unmet Needs

High Disability and Mortality Rates:

DMD is a progressive muscle wasting disease. Patients typically lose the ability to walk around age 10 and die from cardiopulmonary failure between the ages of 20 and 30. With approximately 300,000 cases worldwide and over 70,000 in China, the disease poses a significant social burden.

If a female carrier gives birth to a boy, there is a 50% chance that the child will inherit the disease, creating a high family genetic risk.

Limitations of Existing Treatments:

Current mainstream treatments, including corticosteroids (such as deflazacort) and topical exon-skipping drugs (such as Exondys 51), can only delay the disease, not cure it, and require long-term use with significant side effects.

There is a lack of universal treatments, which only cover specific gene mutation types (such as exon 51/53 skipping), limiting their applicable population. Improved Diagnosis Rate:

With improved medical infrastructure and urbanization, China's DMD diagnosis rate is expected to rise from approximately 30% in 2022 to over 50% in 2025, bringing more patients into the treatment-needing population.

II. R&D Progress and Pipeline Breakthroughs

Breakthroughs in Gene Therapy and Oligonucleotide Technologies:

Gene therapies, such as Sarepta's SRP-9001 (microdystrophin delivered via an AAVrh74 vector) and Faith Pharmaceuticals' BBM-D101 (engineered AAV vector), achieve long-term protein expression with a single dose. Clinical trials have shown a significant increase in the percentage of positive fibers.

Huida Gene's CRISPR-Cas12 gene editing therapy has entered clinical trials, targeting gene mutation repair.

Oligonucleotide therapies, including antisense oligonucleotides (ASOs) and next-generation peptide-coupled oligonucleotides (PPMOs), such as PepGen's PGN-EDO51 and Entrada's ENTR-601-44, enhance cellular uptake and lysosomal escape, improving efficacy and reducing dosage. Active Domestic R&D Pipeline:

Over 10 DMD drugs have entered clinical trials in China, including gene editing (such as Huida Gene's CRISPR-Cas12), AAV gene therapy (Jinwei Bio's JWK007), and mini-protein drugs (Faith Pharmaceuticals' BBM-D101). Some have received FDA orphan drug designation and are expected to be launched after 2026.

III. Policy Support and Optimized Payment Environment

Policy Support for Rare Diseases:

US: The DUX Act extends the market exclusivity period for DMD orphan drugs to 7.5 years, and the accelerated approval process shortens drug launch time by 34%.

China: DMD will be included in the second round of rare disease listings in 2024, promoting domestic R&D. Medical insurance coverage has expanded, with vamorolone included in the national medical insurance negotiations. The price of domestically produced gene therapies is expected to drop below 2 million yuan by 2026.

Improved Affordability:

North America: Commercial insurance companies (such as UnitedHealthcare) have prioritized DMD gene therapy reimbursement, with medical insurance coverage exceeding 80%. In Europe, reimbursement rates for products that pass HTA assessment exceed 80%, but product launches lag 9-15 months behind those in the US.

Asia-Pacific: Markets such as China, Japan, and South Korea are experiencing significant growth, with policies and capital jointly driving therapeutic accessibility.

The DMD therapy market is driven by disease severity, technological breakthroughs, and favorable policies. Gene editing and RNA therapies will dominate the future, but high costs and production capacity bottlenecks (such as AAV vector production) still need to be overcome. Companies need to focus on technological innovation and payment model optimization to address unmet medical needs.

Regional Insights -

The report takes readers on a journey through four key regions: United States, Asia-Pacific, and EMEA. Key nations like the United States, Germany, the United Kingdom, China, Japan, South Korea, and more are thoroughly examined. The data is presented in a timeline from 2024 as the base year, with projections extending to 2031.

North America: United States, Canada, Mexico

Latin America: Brazil and other key markets

Asia Pacific: China, Japan, South Korea, India, ASEAN countries

Europe, Middle East & Africa (EMEA): Major European economies, GCC countries, and African nations

The report provides a region-wise breakdown of market share, consumption trends, and future prospects.

Detailed of Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmentation -

Segmentation By Type :-

Exondys
Emflaza
Translarna

Segmentation By Application -

Hospitals
Clinics
Home Care

This segmentation helps identify high-growth opportunities and niche segments for investors and businesses.

Request for Pre-Order Enquiry On This Exclusive Report @ https://qyresearch.in/pre-order-inquiry/medical-care-global-duchenne-muscular-dystrophy-dmd-therapeutics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Why This Report is a Must-Have -

ᗒ Historical Analysis (2020-2024) & Forecasts (2025-2031): Gain a clear understanding of market trends and future growth potential.

ᗒ Comprehensive Market Segmentation: Detailed breakdown by Type, Application, and Region to identify lucrative opportunities.

ᗒ Competitive Landscape: Insights into key players, their market share, and strategic developments like mergers, acquisitions, and expansion plans.

ᗒ Drivers & Restraints: Understand the factors shaping the market's growth and the challenges that could impact your strategy.

ᗒ Expert Opinions & Market Dynamics: Benefit from expert analysis to navigate market risks and capitalize on emerging trends.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report Objectives -

(1) Analyzing the size of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market on the basis of value and volume

(2) Accurately calculating the market shares, consumption, and other vital factors of different segments of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market

(3) Exploring key dynamics of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market

(4) Highlighting important trends of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market in terms of production, revenue, and sales

(5) Deeply profiling top players of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market and showing how they compete in the industry

(6) Studying manufacturing processes and costs, product pricing, and various trends related to them

(7) Showing the performance of different regions and countries in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market

(8) Forecasting the market size and share of all segments, regions, and the global market.

Important Questions Answered included in the Report:-

(A) What is the market size and growth rate of the global and regional market by various segments?

(B) What is the market size and growth rate of the market for selective Countries?

(C) Which region or sub-segment is expected to drive the market in the forecast period?

(D) What factors are estimated to drive and restrain the market growth?

(E) What are the key technology and market trends shaping the market?

(F) what are the key opportunity in the market?

(G) Who are the leading manufacturers operating in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market?

(H) Which key player accounted for the highest market share?

(I) What are the growth opportunities for the new entrants in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market?

Table of Contents - Major Key Points:

1 Market Overview
1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Introduction
1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast (2020-2031)
1.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends & Drivers
1.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
1.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers & Opportunity
1.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
1.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Ranking (2024)
2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2020-2025)
2.3 Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy (DMD) Therapeutics
2.6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Analysis
2.6.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Exondys
3.1.2 Emflaza
3.1.3 Translarna
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type
3.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (2020-2031)
3.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Home Care
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application
4.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (2020-2031)
4.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region
5.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2020-2025)
5.1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2026-2031)
5.1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
5.2.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
5.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
5.4.2 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
5.5.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
5.6.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
6.3 United States
6.3.1 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
6.3.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
6.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
6.5.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
6.5.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
6.6.2 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
6.7.2 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
6.8.2 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
6.9.2 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
6.9.3 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Sarepta Therapeutics
7.1.1 Sarepta Therapeutics Profile
7.1.2 Sarepta Therapeutics Main Business
7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
7.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
7.1.5 Sarepta Therapeutics Recent Developments
7.2 PTC Therapeutics
7.2.1 PTC Therapeutics Profile
7.2.2 PTC Therapeutics Main Business
7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
7.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
7.2.5 PTC Therapeutics Recent Developments
7.3 Pfizer
7.3.1 Pfizer Profile
7.3.2 Pfizer Main Business
7.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
7.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
7.3.5 Pfizer Recent Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Profile
7.4.2 Bristol-Myers Squibb Main Business
7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
7.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
7.4.5 Bristol-Myers Squibb Recent Developments
7.5 Italfarmaco
7.5.1 Italfarmaco Profile
7.5.2 Italfarmaco Main Business
7.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
7.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
7.5.5 Italfarmaco Recent Developments
7.6 Santhera Pharmaceuticals
7.6.1 Santhera Pharmaceuticals Profile
7.6.2 Santhera Pharmaceuticals Main Business
7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
7.6.5 Santhera Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industrial Chain
8.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

About Us:

QYResearch established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

Contact Us:

Arshad Shaha | Marketing Executive

QY Research, INC.
315 Work Avenue, Raheja Woods,
Survey No. 222/1, Plot No. 25, 6th Floor,
Kayani Nagar, Yervada, Pune 411006, Maharashtra
Tel: +91-8669986909
Emails - arshad@qyrindia.com
Web - https://www.qyresearch.in

This release was published on openPR.